M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals

作     者：Shereen A Saleh Mohamed M Salama Marwan M Alhusseini Ghada A Mohamed 

作者机构：Gastroenterology and Hepatology UnitDepartment of Internal MedicineFaculty of MedicineAin Shams UniversityCairo 11341Egypt 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2020年第26卷第21期

页      面：2864-2876页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Hepatitis C virus Liver fibrosis Human Mac-2 binding protein Antiviral agents Sustained virologic response Elastography 

摘      要：BACKGROUND Assessing liver fibrosis is important for predicting the efficacy of direct-acting antivirals(DAAs)and patient ***-invasive techniques to assess liver fibrosis are becoming ***,serum Mac-2 binding protein glycosylation isomer(M2BPGi)was identified as a non-invasive marker of liver *** To investigate the diagnostic accuracy of M2BPGi in assessing liver fibrosis in patients with chronic hepatitis C(CHC)treated with *** From December 2017 to August 2018,80 treatment-naive adult patients with CHC who were eligible for DAAs therapy were consecutively enrolled in this observational cohort *** 12 weeks,65 patients were treated with sofosbuvir/daclatasvir,and 15 patients were treated with sofosbuvir/daclatasvir and a weight-based dose of ribavirin at knowledge and technology association for hepatitis C management clinic,Cairo,*** measured serum M2BPGi levels,PAPAS index,fibrosis-4(FIB-4)score and liver stiffness measurements(LSM)at baseline and 12 weeks after the end of *** M2BPGi levels were measured using enzyme-linked immunosorbent *** All patients achieved sustained virologic response(SVR12)(100%).Serum M2BPGi levels,LSM,FIB-4 score and PAPAS index decreased significantly at SVR12(P0.05).Serum M2BPGi levels correlated positively with LSM at baseline and SVR12(P0.001).At baseline,compared with the FIB-4 score and PAPAS index,M2BPGi was the best marker to distinguish patients with grade F4 fibrosis(AUC=0.801,P0.001),patients with grade F2 from grade F0-1 fibrosis(AUC=0.713,P=0.012),patients with grade F3-4 from grade F0-2 fibrosis(AUC=0.730,P0.001),and patients with grade F2-4 from grade F0-1 fibrosis(AUC=0.763,P0.001).At SVR12,M2BPGi had the greatest AUCs for differentiating patients with grade F4 fibrosis(AUC=0.844,P0.001),patients with grade F3 from grade F0-2 fibrosis(AUC=0.893,P=0.002),patients with grade F3-4 from grade F0-2 fibrosis(AUC=0.891,P0.001),and patients with grad